Inmune Bio (INMB) Current Assets (2017 - 2026)
Inmune Bio (INMB) posted Current Assets of $22.8 million for Q1 2026, down 23.64% sequentially from $29.9 million in Q4 2025, and up 8.88% YoY from $21.0 million in Q1 2025.
Inmune Bio (INMB) Current Assets (2017 - 2026) Analysis & Trends
Inmune Bio has reported Current Assets for 10 years, with the latest figure at $22.8 million in Q1 2026.
- Quarterly Current Assets rose 8.88% year-over-year to $22.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.8 million (up 8.88% YoY) and the FY2025 annual result came in at $29.9 million, up 31.88% from the prior year.
- Current Assets eased to $22.8 million in Q1 2026 per INMB's latest filing, from $29.9 million in the prior quarter.
- Over five years, Current Assets peaked at $77.1 million in Q1 2022 and troughed at $21.0 million in Q1 2025.
- A 5-year average of $43.4 million and a median of $36.0 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2024: Current Assets soared 60.15% in 2022, then tumbled 47.57% in 2024.
- Over 5 years, Current Assets stood at $64.7 million in 2022, then tumbled by 38.24% to $39.9 million in 2023, then plunged by 43.26% to $22.7 million in 2024, then jumped by 31.88% to $29.9 million in 2025, then dropped by 23.64% to $22.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $22.8 million, $29.9 million, and $30.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 1.76 Bn |
| 10 | Inmune Bio | 61.32 Mn | 42.91 Mn | - | 23.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.80 Mn |
| Mar 31, 2026 | 22.82 Mn |
| Dec 31, 2025 | 29.89 Mn |
| Sep 30, 2025 | 30.67 Mn |
| Jun 30, 2025 | 36.03 Mn |
| Mar 31, 2025 | 20.96 Mn |
| Dec 31, 2024 | 22.66 Mn |
| Sep 30, 2024 | 35.85 Mn |
| Jun 30, 2024 | 35.50 Mn |
| Mar 31, 2024 | 29.82 Mn |
| Dec 31, 2023 | 39.94 Mn |
| Sep 30, 2023 | 45.61 Mn |
| Jun 30, 2023 | 52.61 Mn |
| Mar 31, 2023 | 56.88 Mn |
| Dec 31, 2022 | 64.68 Mn |
| Sep 30, 2022 | 66.66 Mn |
| Jun 30, 2022 | 70.55 Mn |
| Mar 31, 2022 | 77.06 Mn |
| Dec 31, 2021 | 82.61 Mn |
| Sep 30, 2021 | 90.93 Mn |